PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Friday broker round-up UPDATE

Fri, 25th Jul 2014 09:29

African Barrick Gold: Investec places both its target price (prev.: 212p) and its sell recommendation under review. Westhouse Securities ups target price from 250p to 285p upgrading from neutral to add.Barclays: Deutsche Bank cuts target price from 300p to 275p staying with its buy recommendation.Barr AG: Investec ups target price from 645p to 661p retaining an add rating.Bodycote: Berenberg ups target price from 759p to 776p upgrading from hold to buy.BSkyB: Westhouse Securities places both its target price (prev.: 985p) and its neutral rating under review. Investec places its target price (prev.: 825p) and its reduce rating under review.bwin.party: Credit Suisse lowers target price from 99p to 88p and reiterates an underperform rating.CSR: Deutsche Bank raises target price from 400p to 420p and maintains a buy recommendation.De La Rue: Numis upgrades from hold to add with a target price of 845p.Drax Group: Societe Generale cuts target price from 680p to 630p downgrading to sell.easyJet: UBS reduces target price from 2100p to 1930p and keeps a buy recommendation.Electrocomponents: Jefferies cuts target price from 250p to 230p leaving its hold recommendation unchanged. Deutsche Bank cuts target price from 290p to 265p and retains a hold recommendation. Canaccord Genuity cuts target price from 356p to 313p retaining a buy recommendation. Credit Suisse cuts target price from 260p to 220p and stays with its underperform rating.GlaxoSmithKline: UBS reduces target price from 1500p to 1380p downgrading from neutral to sell.Howden Joinery: Canaccord Genuity raises target price from 305p to 410p and maintains a buy recommendation.InterContinental Hotels Group: Nomura raises target price from 2065p to 2365p staying with its neutral rating.Interserve: Berenberg initiates with a target price of 750p and a buy recommendation.Kingfisher: Deutsche Bank cuts target price from 460p to 430p and stays with its buy recommendation. Societe Generale cuts target price from 353p to 320p and skeeps a hold recommendation-Lancashire Holdings: Deutsche Bank cuts target price from 762p to 724p and maintains a buy recommendation. Canaccord Genuity cuts target price from 690p to 670p and retains a hold recommendation.Lonmin: Investec places both its target price(prev.: 238p) and its sell recommendation under review.Marston's: Beaufort upgrades to buy.Mitchells & Butlers: Beaufort initiates with a buy recommendation.Petrofac: Societe Generale reduces target price from 1480p to 1220p downgrading to hold.Provident Financial: Societe Generale increases target price from 1560p to 2270p and reiterates a hold recommendation.Rathbone Brothers: Numis ups target price from 1825p to 1860p and reiterates a hold recommendation.Reckitt Benckiser: Jefferies raises target price from 4500p to 5000p and keeps a hold recommendation.Reed Elsevier: Nomura ups target price from 1050p to 1080p maintaining a buy recommendation. Morgan Stanley takes target price from 1000p to 1030p retaining an overweight rating. Numis raises target price from 1031p to 1130p staying with an add rating.Rexam: Jefferies downgrades from buy to hold with a target price of 550p.Ricardo: Berenberg initiates with a target price of 735p and retains a buy recommendation.Spectris: Numis downgrades from add to hold with a target price of 2300p. Investec places both its target price (prev.: 2720p) and its buy recommendation under review.Stagecoach: Nomura moves target price from 390p to 400p staying with its buy recommendation.Tate & Lyle: UBS lowers target price from 630p to 615p and reiterates a sell recommendation. Canaccord Genuity cuts target price from 660p to 640p and stays with its hold recommendation. Credit Suisse cuts target price from 540p to 630p leaving its underperform rating unaltered.Topps Tiles: Berenberg initiates with a target price of 170p and a buy recommendation.
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.